Log in to your Inderes Free account to see all free content on this page.
BioArctic
145.7 SEK -34.25%6 investors are following this company
BioArctic is a research company. The greatest business focus is found in the research and development of treatments and antibodies for diseases that affect the nervous system. Examples of various diseases mainly include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. The company was founded in 2003 and is headquartered in Stockholm, Sweden.
Revenue
-
EBIT %
-
P/E
56.04
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BIOA B
Daily low / high price
142.9 / 226
SEK
Market cap
12.87B SEK
Turnover
360.29M SEK
Volume
2.3M
Latest videos
Financial calendar
Interim report
29.08.2024
Interim report
14.11.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Lars Lannfelt | 33.4 % | 49.2 % |
Pär Gellerfors | 21.6 % | 32.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BioArctic: CHMP has adopted a negative opinion on lecanemab for the EU
BioArctic: Long-term treatment data for lecanemab to be presented at AAIC 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio